IDEA-FAST’s Post

US Rare Disease Biotech leaders: A quick 5-minute read on leveraging HTA assessments to strengthen your US payer negotiations. https://lnkd.in/ewC8CKt7 Follow Partner Rare for more bite-sized insights. If you're approaching a new Rare Disease project, get in touch - no pressure, just helpful expertise. 💚 #raredisease #biotech #pharma #HTA #marketentry #FDA #EMA #PartnerRare

Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/gxNGFuzH 👇 #Chemenu #Inventiva #LEGEND #lanifibranor #empagliflozin #MASH/NASH #Type2Diabetes #endpoint #PPAR #antifibrotic #anti-inflammatory #vascularandmetabolicchanges #drugdiscovery #buildingblocks

A downstream approach to neurodegenerative conditions has been questioned recently, as was the amyloid hypothesis in AD. The healthcare regulators have been seeing the safety concerns around ARIA and inflammatory complications that were not offset by tangible clinical benefits. #upstreammedicine #preventiveneurology #restorativeneurology In summary: EU regulator cites safety concerns, small benefit Eisai, Biogen to seek re-examination of decision The drug's launch in the U.S. has been slow Biogen shares fall 7%, rival Lilly slips 1% https://lnkd.in/gst85yyY

Exciting News! 🚀 The diuretics market is on the rise, reaching $0.75 billion in 2024 with a notable CAGR of 4.8%. Key drivers include the prevalence of chronic diseases, an aging population, and pharmaceutical innovation. The forecast anticipates continued growth, reaching $0.88 billion in 2028 with a CAGR of 4.2%, driven by factors like hypertension, emerging markets, government initiatives, and a focus on preventive healthcare. Innovative trends shaping the future include personalized medicine, advanced drug formulations, and telehealth solutions. Cardiac disorders contribute to market growth, with industry giants like Merck, Pfizer, and Novartis playing a pivotal role. Explore more in The Diuretics Market Report 2024 here. https://lnkd.in/gjDhu-55 #Pharmaceuticals #BusinessResearch #CardiacHealth #GlobalMarket #DigitalHealth #CAGR #tbrc

In a new study, Novo Nordisk's liraglutide daily injections, currently used to treat diabetes and obesity, have shown promise in slowing Alzheimer's progression. The mid-stage clinical trial indicates that liraglutide may protect brain function, with patients experiencing an 18% slower cognitive decline and significantly less brain shrinkage. Other drugs that have been widely known for secondary uses include minoxidil, originally approved for treating high blood pressure, and now recognized as one of the most successful hair regrowth treatments on the market, and aspirin, developed as a pain reliever, which is now widely used to prevent blood clots and to reduce the risk of heart attack and stroke. These findings underscore the benefits of using clinical trials to discover additional uses for approved drugs, a method that could speed up drug delivery and offer new hope to those suffering with a range of illnesses. Learn about how you can speed up your upcoming clinical trials with automated data streaming. https://buff.ly/46vyz85 #ClinicalTrials #PharmaceuticalResearch #HealthcareInnovation

H.C Weinwright analyst: #CardiolRx Poised for the Final Stretch; Initiating With a Buy Rating and $9 PT (1) CardiolRx is a Phase 2 stage, pharmaceutical-grade, proprietary cannabidiol oral solution in development as a treatment for recurrent #pericarditis (RP) and acute #myocarditis (AM); (2) Cardiol’s use of a deliberate, scientific evidence-based approach to CardiolRx clinical advancement creates a significant barrier to entry; and (3) CardiolRx targets RP and AM, heart disease indications with significant unmet medical need with high potential to make CardiolRx a blockbuster drug that we forecast could achieve >$1.3B in peak annual sales. #CRDL #Cardiol #HeartDisease #CVD

Posaconazole is a drug for antifungal treatment and prophylaxis. Dose individualization of this drugs is of utmost importance as achieving adequate antifungal exposure is associated with improved outcome. Model-informed precision dosing (MIPD) is the next step in tailored antifungal treatment. In the most recent edition of the journal "clinical pharmacokinetics" Anouk Jansen shows the development and validation of a model-informed precision dosing algorithm for posaconazole, that can be directly implemented in clinical practice. Read more about it here: https://lnkd.in/dZ3tNPXZ

🚀 Forecasting the Future of PAH Therapeutics: Market Trends and Developments The Pulmonary Arterial Hypertension (PAH) treatment landscape is seeing exciting changes as established therapies continue to perform and new options advance through development. 📊💊 Projections show sustained growth for therapies like macitentan and treprostinil, while new entrants like sotatercept and selexipag (currently in Phase III) have the potential to reshape the treatment paradigm. One standout is sotatercept by Merck, anticipated to see a substantial rise in sales from $552M in 2024 to over $6B by 2030. 📈💡 Additionally, promising new therapies like brilaroxazine hydrochloride and ralinepag XR in early development stages underscore the industry’s dedication to innovation and improved patient outcomes. As PAH treatment options evolve, it’s clear that the future holds exciting opportunities for patients and healthcare providers alike! 💡💉 Interactive Graph: https://lnkd.in/g6R_bKHE #PAH #PulmonaryArterialHypertension #HealthcareInnovation #Biopharma #Therapeutics #DrugDevelopment

We have compiled the week's top news for you at Market Access Today! - The FDA has approved eflornithine (Iwilfin), marking a significant milestone in treating high-risk neuroblastoma (HRNB)... (https://lnkd.in/dXqqPUq9) - In a remarkable development, scientists are actively working on a portable health monitoring device that empowers women to track and monitor their health and hormone levels effortlessly, even on the go... (https://lnkd.in/d2z_93rK) - WELIREG, a drug designed for adult patients with renal cell carcinoma (RCC), has been approved by the FDA... (https://lnkd.in/dVWiF-Wi) - In the recent year, U.S. health spending saw an increase of 4.1%, reaching a total of $4.5 trillion... (https://lnkd.in/dBYwMNZr) - The updated 2023 IQVIA report, ‘The Impact of Biosimilar Competition in Europe’, unveiled at the European Commission’s annual stakeholder event, delves into the evolution of the biopharmaceutical market in the wake of biosimilar competition’s introduction in Europe... (https://lnkd.in/d6YGrtxb) Stay Informed, Stay Ahead with Market Access Today: marketaccesstoday.com #marketacces #reimbursementpolicies #patientaccessschemes #healthcareindustry #pricing #healtheconomics #pharmacoeconomics #health #pharmaceuticals #medicaldevices #HEOR #HTA #RWE #insights #trends #updates FDA IQVIA

Thoughts on this? >> #ADA24: Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #productmarketing #healthcare